Risks of hepatotoxicities during the intensive phase of tuberculosis treatment: A hospital-based case control study

Abstract

Objective: To identify factors associated with hepatotoxicity during the intensive phase of treatment in tuberculosis (TB) patients.

Methods: A case-control study was conducted of TB patients treated with first-line anti-TB drugs from 2013 to 2020. Cases were defined as patients who developed hepatotoxicity, while controls were those without hepatotoxicity, at a 1:2 ratio. Controls were randomly selected from the same hospitals as the cases. The primary outcome was the occurrence of hepatotoxicity during the intensive treatment phase, with data retrospectively collected from medical records. Descriptive statistics and multiple logistic regression with backward elimination were used for analysis.

Results: Among 3021 tuberculosis patients who received first-line anti-tuberculosis regimen, 50 had abnormal liver function and 14 developed hepatotoxictiy. In addition, 2957 patients had normal liver function and 128 served as controls for this analysis. Multiple logistic regression analysis revealed that female patients had about twice the risk of hepatotoxicity compared to males (adjusted OR 2.25, 95% CI 1.11-4.59), and patients with HIV coinfection were nearly 10 times more likely to develop hepatotoxicity than those without HIV (adjusted OR 9.74, 95% CI 3.12-30.41).

Conclusions: Female sex and HIV coinfection were found to be significant risk factors for hepatotoxicity during the intensive phase of TB treatment. Enhanced monitoring and preventive strategies are recommended for these high-risk groups to reduce the risk of hepatotoxicity.

Keywords

Hepatotoxicity / Anti-tuberculosis drugs / First-line drugs / Tuberculosis

References

[1] Mohammadnabi N, Shamseddin J, Emadi M, Bodaghi AB, Varseh M, Shariati A, et al. Mycobacterium tuberculosis: The mechanism of pathogenicity, immune responses, and diagnostic challenges. J Clin Lab Anal 2024; 38(23): e25122.

[2] Onaghinor IJ, Achusi IB, Ariyo OE. Tuberculosis of the breast: A rare extra-pulmonary presentation of tuberculosis. J Infect Dev Ctries 2024; 18(7): 1141-1144.

[3] Yang H, Ruan X, Li W, Xiong J, Zheng Y. Global, regional, and national burden of tuberculosis and attributable risk factors for 204 countries and territories, 1990-2021: A systematic analysis for the Global Burden of Diseases 2021 study. BMC Public Health 2024; 24(1): 3111.

[4] Safiri S, Carson-Chahhoud K, Noori M, Nejadghaderi SA, Sullman MJM, Ahmadian Heris J, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: Results from the Global Burden of Disease Study 2019. BMJ 2022; 378: e069679.

[5] Kasznia-Brown J. Global resources in the fight against tuberculosis. Pediatr Radiol 2023; 53(9): 1746-1752.

[6] Vasiliu A, Martinez L, Gupta RK, Hamada Y, Ness T, Kay A, et al. Tuberculosis prevention: Current strategies and future directions. Clin Microbiol Infect 2024; 30(9): 1123-1130.

[7] Giusti A, Carbonetta L, Fratini F, Spatola G, Panerai F, Pardini S, et al. An overview of a re-emerging disease in Italy: Bovine tuberculosis outbreaks in cattle from MTBC-free territories. Pathogens 2024; 13(11): 962.

[8] Ding C, Hu M, Shangguan Y, Guo W, Wang S, Feng X, et al. Epidemic trends in high tuberculosis burden countries during the last three decades and feasibility of achieving the global targets at the country level. Front Med (Lausanne) 2022; 9: 798465.

[9] Melnychuk L, Perlman-Arrow S, Lisboa Bastos M, Menzies D. A systematic review and meta-analysis of tuberculous preventative therapy adverse events. Clin Infect Dis 2023; 77(2): 287-294.

[10] Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167(11): 1472-1477.

[11] Lewis JH, Korkmaz SY, Rizk CA, Copeland MJ. Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis. Expert Opin Drug Saf 2024; 23(9): 1093-1107.

[12] Hemmarak K, Chaimay B, Woradet S. Association of comorbidities and results of laboratory testing before the beginning treatment with hepatotoxicity due to anti-tuberculosis drug: Acedemic review. KKU 2021; 14(3): 78-93.

[13] World Health Organization. International statistical classification of diseases and related health problems: 10th revision (ICD-10). 5th ed. Geneva: World Health Organization; 2016.

[14] Sharma SK, Singla R, Sarda P, Mohan A, Makharia G, Jayaswal A, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010; 50(6): 833-839.

[15] Sandhu N, Navarro VJ. Drug-induced liver injury in GI practice. Hepatol Commun 2020; 4(5): 631-645.

[16] Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: Treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016; 63(7): e147-195.

[17] Bernard R. Fundamentals of biostatistics. 5th ed. Duxbury: Thomson Learning; 2000.

[18] Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. 3rd ed. John Wiley & Sons; 2003.

[19] Ngamjarus C. n4Studies: Sample size calculation for an epidemiological study on a smart phone. Siriraj Med J 2016; 68(3): 160-170.

[20] Suh JI. Drug-induced liver injury. Yeungnam Univ J Med 2020; 37(1): 2-12.

[21] Sayaf K, Gabbia D, Russo FP, De Martin S. The role of sex in acute and chronic liver damage. Int J Mol Sci 2022; 23(18): 10654.

[22] Guy J, Peters MG. Liver disease in women: The influence of gender on epidemiology, natural history, and patient outcomes. Gastroenterol Hepatol (N Y) 2013; 9(10): 633-639.

[23] Shu CC, Lee CH, Lee MC, Wang JY, Yu CJ, Lee LN. Hepatotoxicity due to first-line anti-tuberculosis drugs: A five-year experience in a Taiwan medical centre. Int J Tuberc Lung Dis 2013; 17(7): 934-939.

[24] Satyaraddi A, Velpandian T, Sharma SK, Vishnubhatla S, Sharma A, Sirohiwal A, et al. Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. Int J Tuberc Lung Dis 2014; 18(2): 188-195.

[25] Babalık A, Arda H, Bakırcı N, Ağca S, Oruç K, Kızıltaş S, et al. Management of and risk factors related to hepatotoxicity during tuberculosis treatment. Tuberk Toraks 2012; 60(2): 136-144.

[26] Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167(11): 1472-1477.

[27] Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother 2004; 38(6): 1074-1079.

[28] Khalili H, Dashti-Khavidaki S, Rasoolinejad M, Rezaie L, Etminani M. Anti-tuberculosis drugs related hepatotoxicity; incidence, risk factors, pattern of changes in liver enzymes and outcome. DARU 2009; 17(3): 163-167.

[29] Lomtadze N, Kupreishvili L, Salakaia A, Vashakidze S, Sharvadze L, Kempker RR, et al. Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis. PLoS One 2013; 8(12): e83892.

[30] Shen X, Yuan Z, Mei J, Zhang Z, Guo J, Wu Z, et al. Anti-tuberculosis drug-induced liver injury in Shanghai: Validation of Hy’s Law. Drug Saf 2014; 37(1): 43-51.

[31] Marzuki OA, Fauzi AR, Ayoub S, Kamarul Imran M. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Singapore Med J 2008; 49(9): 688-693.

[32] Harries AD, Dye C. Tuberculosis. Ann Trop Med Parasitol 2006; 100(5-6): 415-431.

[33] Chaimay B, Woradet S, Chantutanon S, Phuntara S, Suwanna K. Mortality among HIV/AIDS patients coinfected with Mycobacterium tuberculosis in Southern Thailand. Southeast Asian J Trop Med Public Health 2013; 44(4): 641-648.

[34] Kaspar MB, Sterling RK. Mechanisms of liver disease in patients infected with HIV. BMJ Open Gastroenterol 2017; 4(1): e000166.

[35] Nader LA, de Mattos AA, Picon PD, Bassanesi SL, De Mattos AZ, Pineiro Rodriguez M. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: Is anti-HCV a risk factor? Ann Hepatol 2010; 9(1): 70-74.

[36] Yimer G, Aderaye G, Amogne W, Makonnen E, Aklillu E, Lindquist L, et al. Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients. PLoS One 2008; 3(3): e1809.

[37] Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: A case-control study. Thorax 1996; 51(2): 132-136.

[38] Zeleke A, Misiker B, Yesuf TA. Drug-induced hepatotoxicity among TB/HIV co-infected patients in a referral hospital, Ethiopia. BMC Res Notes 2020; 13(1): 2.